Idiopathic Pulmonary Fibrosis Clinical Trials

We anticipate a number of observational studies will be developed from the data collected in the IPF-PRO registry. All planned analyses will be performed by the DCRI statistical team. Planning of the analyses will be done as a coordinated effort between the teams at the DCRI and Boehringer Ingelheim (refer ...

Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry

To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in IPF patients with advanced lung function impairment.

Winthrop University Hospital Clinical Trials Center is seeking volunteers who have been diagnosed with Idiopathic Pulmonary Fibrosis, a condition which decreases lung function. This study is testing an investigational medication to see if it is safe and effective. Eligible participants will receive study related medical care and study medication at ...

DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA. Some people with short telomeres or other gene changes can develop diseases of the bone marrow, lung, and liver. Researchers want to see ...

To evaluate the change in 6MWD after 8 weeks of treatment with iNO vs. 8 weeks on placebo as measured by 6MWT (6 minute walk test).

This is a proof of concept study to evaluate the efficacy, safety and tolerability of ABT in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research ...

The investigators hypothesize that PR service with supplemented oxygen supply regardless of hypoxemia may have significantly better short-term effects in patients with IPF. The study will take place in Corfu General Hospital, by the Departments of Pulmonary Medicine and Physiotherapy and Rehabilitation, respectively. Study participants will be divided in two ...

Pulmonary fibrosis can be secondary to connective-tissue disease, environmental exposure, or drug toxicity, but it can also appear sporadically without any known cause, i.e. idiopathic interstitial pneumonitis (IIP). Idiopathic pulmonary fibrosis (IPF) is the commonest IIP and usually follows a rapidly progressive course with a short median survival time. IPF ...